{
    "clinical_study": {
        "@rank": "60493", 
        "arm_group": [
            {
                "arm_group_label": "Healthy", 
                "arm_group_type": "Experimental", 
                "description": "Healthy participants will receive ketamine in the scan"
            }, 
            {
                "arm_group_label": "Depressed", 
                "arm_group_type": "Experimental", 
                "description": "Depressed participants will receive ketamine in the scan"
            }
        ], 
        "brief_summary": {
            "textblock": "This study is looking at the mechanisms underlying the behavioral effects of ketamine in\n      healthy and depressed individuals."
        }, 
        "brief_title": "Examining The Effect Of Ketamine On Glutamate/Glutamine Cycling", 
        "condition": "Depression", 
        "condition_browse": {
            "mesh_term": [
                "Depression", 
                "Depressive Disorder"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Healthy Group\n\n        Inclusion Criteria:\n\n          -  Male or female between the ages of 21-45 years.\n\n          -  Able to provide written informed consent.\n\n          -  Able to read and write English.\n\n        Exclusion Criteria:\n\n          -  Personal or first-degree family member with history of mood, anxiety, or psychotic\n             axis I DSM-IV disorders confirmed after comprehensive psychiatric evaluation.\n\n          -  Any history of serious medical or neurological illness.\n\n          -  Any signs of major medical or neurological illness on examination or as a result of\n             ECG screening or laboratory studies.\n\n          -  Lifetime history of psychoactive substance or alcohol dependence or substance or\n             alcohol abuse (other than nicotine or caffeine abuse), or drinking more that 5\n             drinks/week during the last year.\n\n          -  Abnormality on physical examination.\n\n          -  A positive pre-study (screening) urine drug screen or, at the study physician's\n             discretion on any drug screens given before the scans.\n\n          -  Pregnant or lactating women or a positive urine pregnancy test for women of\n             child-bearing potential at screening or prior to any imaging day.\n\n          -  Subjects who test positive for HIV or viral hepatitis (hepatitis B and/or C)\n\n          -  Has received either prescribed or over-the-counter (OTC) centrally active medicine or\n             herbal supplements within the week prior to the MRI scan.\n\n          -  Any history indicating learning disability, mental retardation, or attention deficit\n             disorder.\n\n          -  Known sensitivity to ketamine.\n\n          -  Body circumference of 52 inches or greater.\n\n          -  Body weight of 250 pounds or greater.\n\n          -  History of claustrophobia.\n\n          -  Presence of cardiac pacemaker or other electronic device or ferromagnetic metal\n             foreign bodies in vulnerable positions as assessed by a standard pre-MRI screening\n             questionnaire.\n\n          -  Donation of blood in excess of 500 mL within 56 days prior to dosing.\n\n          -  History of sensitivity to heparin or heparin-induced thrombocytopenia.\n\n          -  Resting blood pressure lower than 90/60 or higher than 150/90,or resting heart rate\n             lower than 45/min or higher than 100/min.\n\n        Depression Group\n\n        Inclusion Criteria:\n\n          -  Male or female between the ages of 21-65 years.\n\n          -  Able to provide written informed consent.\n\n          -  Current MDD Single Episode (296.2x) or Recurrent (296.3x), as determined by the\n             Structured Clinical Interview for DSM-IV (SCID) patient edition\n\n          -  Montgomery Asberg Depression Rating Scale (MADRS) score of 18 or higher at baseline\n             and start of first 13C-MRS.\n\n          -  Quick Inventory of Depressive Symptoms - Self-Report (QIDS-SR16) score of 19 or\n             higher at baseline and start of first 13C-MRS.\n\n          -  No psychotropic medications for 2 or more weeks (4 weeks for Fluoxetine) prior to\n             first 13C-MRS.\n\n          -  Be able to understand and speak English.\n\n        Exclusion Criteria:\n\n          -  Patients with a history of DSM-IV-TR diagnosis of bipolar disorder or schizophrenia\n             or schizoaffective disorder or currently exhibiting psychotic features associated\n             with their depression; dementia or suspicion thereof, is also exclusionary.\n\n          -  First-degree family member with history of schizophrenia or any other psychotic\n             disorder.\n\n          -  Serious suicide or homicide risk, as assessed by evaluating clinician; A serious\n             suicide risk will be considered an inability to control suicide attempts, imminent\n             risk of suicide in the investigator's judgment, or a history of serious suicidal\n             behavior, which is defined using the Columbia-Suicide Severity Rating Scale (C-SSRS)\n             as either (1) one or more actual suicide attempts in the 3 years before study entry\n             with the lethality rated at 3 or higher, or (2) one or more interrupted suicide\n             attempts with a potential lethality judged to result in serious injury or death.\n\n          -  Substance abuse or dependence during the 12 months prior to screening.\n\n          -  Any history of serious medical or neurological illness.\n\n          -  Any signs of major medical or neurological illness.\n\n          -  Abnormality on physical examination.  A subject with a clinical abnormality may be\n             included only if the study physician considers the abnormality will not introduce\n             additional risk factors and will not interfere with the study procedure.\n\n          -  A positive pre-study (screening) urine drug screen or on any drug screens given\n             before the scans.\n\n          -  Pregnant or lactating women or a positive urine pregnancy test for women of\n             childbearing potential at screening or prior to any imaging day.\n\n          -  Subjects who test positive for HIV or viral hepatitis (hepatitis B and/or C)\n\n          -  Any history indicating learning disability, or mental retardation.\n\n          -  Known sensitivity to ketamine.\n\n          -  Body circumference of 52 inches or greater.\n\n          -  Body weight of 250 pounds or greater.\n\n          -  History of claustrophobia.\n\n          -  Presence of cardiac pacemaker or other electronic device or ferromagnetic metal\n             foreign bodies in vulnerable positions as assessed by a standard pre-MRI screening\n             questionnaire.\n\n          -  Donation of blood in excess of 500 mL within 56 days prior to dosing.\n\n          -  History of sensitivity to heparin or heparin-induced thrombocytopenia.\n\n          -  Resting blood pressure lower than 90/60 or higher than 150/90,or resting heart rate\n             lower than 45/min or higher than 100/min."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "Accepts Healthy Volunteers", 
            "maximum_age": "65 Years", 
            "minimum_age": "21 Years"
        }, 
        "enrollment": {
            "#text": "36", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "November 19, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02037035", 
            "org_study_id": "1305011972"
        }, 
        "intervention": {
            "arm_group_label": [
                "Healthy", 
                "Depressed"
            ], 
            "intervention_name": "Ketamine", 
            "intervention_type": "Drug"
        }, 
        "intervention_browse": {
            "mesh_term": "Ketamine"
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "No", 
        "lastchanged_date": "January 14, 2014", 
        "location": {
            "facility": {
                "address": {
                    "city": "New Haven", 
                    "country": "United States", 
                    "state": "Connecticut", 
                    "zip": "06511"
                }, 
                "name": "Yale Depression Research Program"
            }, 
            "investigator": {
                "last_name": "Chadi Abdallah, MD", 
                "role": "Principal Investigator"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "official_title": "Examining The Effect Of Ketamine On Glutamate/Glutamine Cycling", 
        "overall_contact": {
            "email": "chadi.abdallah@yale.edu", 
            "last_name": "Chadi Abdallah"
        }, 
        "overall_official": {
            "affiliation": "Yale School of Medicine", 
            "last_name": "Chadi Abdallah, MD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "United States: Institutional Review Board", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 0", 
        "primary_completion_date": {
            "#text": "July 2018", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "Glutamate Metabolism", 
            "safety_issue": "No", 
            "time_frame": "40-75 minutes"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02037035"
        }, 
        "responsible_party": {
            "investigator_affiliation": "Yale University", 
            "investigator_full_name": "Chadi Abdallah", 
            "investigator_title": "Assistant Professor", 
            "responsible_party_type": "Principal Investigator"
        }, 
        "source": "Yale University", 
        "sponsors": {
            "collaborator": [
                {
                    "agency": "National Institute of Mental Health (NIMH)", 
                    "agency_class": "NIH"
                }, 
                {
                    "agency": "American Psychiatric Association", 
                    "agency_class": "Other"
                }
            ], 
            "lead_sponsor": {
                "agency": "Yale University", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "July 2013", 
        "study_design": "Allocation: Non-Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Basic Science", 
        "study_type": "Interventional", 
        "verification_date": "January 2014"
    }
}